Dr Reddys Laboratories (RDY) EBITDA Margin Growth (3y) (2012 - 2026)
Powered by 
Analysis
Dr Reddys Laboratories (RDY) EBITDA Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn | 1,129.00 |
| 2 | Viatris | 19.17 Bn | 18.28 Bn | 1.46 Bn | -925.00 |
| 3 | Dr Reddys Laboratories | 9.88 Bn | 9.71 Bn | 396.53 Mn | -2,128.00 |
| 4 | Amneal Pharmaceuticals | 5.47 Bn | 5.34 Bn | 334.51 Mn | 293.00 |
| 5 | Bausch Health Companies | 2.33 Bn | 494.50 Mn | 2.10 Bn | 693.00 |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -230,408.00 |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 457.00 |
| 8 | Amphastar Pharmaceuticals | 994.21 Mn | 704.09 Mn | 93.47 Mn | -372.00 |
| 9 | Fennec Pharmaceuticals | 400.89 Mn | 359.65 Mn | 17.15 Mn | 15,005.00 |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,128.00 |
| Mar 31, 2026 | -2,438.00 |
| Dec 31, 2025 | -337.00 |
| Sep 30, 2025 | -438.00 |
| Jun 30, 2025 | -297.00 |
| Mar 31, 2025 | 1,795.00 |
| Dec 31, 2024 | 1,194.00 |
| Sep 30, 2024 | 449.00 |
| Jun 30, 2024 | 238.00 |
| Mar 31, 2024 | 770.00 |
| Dec 31, 2023 | 783.00 |
| Sep 30, 2023 | 2,152.00 |
| Jun 30, 2023 | 898.00 |
| Mar 31, 2023 | 784.00 |
| Dec 31, 2022 | 472.00 |
| Sep 30, 2022 | 3,770.00 |
| Jun 30, 2022 | 811.00 |
| Mar 31, 2022 | -1,051.00 |
| Dec 31, 2021 | -279.00 |
| Sep 30, 2021 | 250.00 |